기본 정보
- CAS
141625-93-6- 표준 SMILES
CCCCc1oc2ccc(NS(C)(=O)=O)cc2c1C(=O)c1ccc(OCCCN(CCCC)CCCC)cc1.Cl- InChIKey
DWKVCQXJYURSIQ-UHFFFAOYSA-N- 분자식
- C31H45ClN2O5S
- 평균 분자량
- 593.2 g/mol
- 단동위원소 질량
- 592.27377122
개요
Dronedarone Hydrochloride is the hydrochloride salt form of dronedarone, an orally bioavailable benzofuran derivative, with anti-arrhythmic activity. Upon oral administration, and although the exact mechanism of action through which dronedarone exerts its anti-arrhythmic effect has not been fully elucidated, it inhibits multiple voltage-gated ion channels, including sodium, potassium, and calcium ion channels, and restores the normal sinus rhythm and reduces heart rate in atrial fibrillation. It also non-competitively antagonizes adrenergic receptors.
이름 및 식별자
- 우선 이름
- Dronedarone Hydrochloride
- IUPAC
- N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide;hydrochloride
- 영어명
- Dronedarone hydrochloride
- 분자식
- C31H44N2O5S.ClH
- 분자량
- 593.22
이름 및 동의어
이름 더 보기
데이터베이스 식별자
- CAS
141625-93-6- PubChem CID
- 219025
- DTXSID
DTXSID30161779- ChEMBL
CHEMBL1201729- UNII
- FA36DV299Q
- EC Number
- 630-355-2
물성
구조 계산 물성
- 극성 표면적
- 97.2 Ų
- 수소 결합 공여자 수
- 2
- 수소 결합 수용자 수
- 7
- 회전 가능 결합 수
- 18
- 무거운 원자 수
- 40
- 형식 전하
- 0
- 복잡도
- 800
실험 및 물리화학적 성질
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
물리화학적 성질
- 녹는점
- NA (low-melting)
- 저장 조건
- 2 · 2-8°C
- 용해도
- 15 mg/mL, · DMSO: 용해성15mg/mL, 투명
- 물리적 상태
- 가루
- 색상
- 흰색에서 황백색까지
- Merck
- 14 · 14,3449
- 안정성
- 흡습성
- InChIKey
- DWKVCQXJYURSIQ-UHFFFAOYSA-N
- SMILES
- Cl.CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c2c(CCCC)oc3ccc(NS(C)(=O)=O)cc23
화학적 성질
Pale Yellow Solid
안전 및 규제
GHS 분류
GHS Classification
This chemical does not meet GHS hazard criteria for 8.3% (1 of 12) of reports.
Warning
H302 (33.3%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P260, P261, P263, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 12 reports by companies from 12 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
유해성 정보
독성 정보
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Dronedarone hydrochloride
vMost-DILI-concern
7
Warnings & precautions
DOI:10.1016/j.drudis.2016.02.015
안전 데이터
- wgk
- 3
- ridadr
- UN 3077 9 / PGIII
- HS 번호
- 2935904000
- 스토리지 클래스
- 11 - Combustible Solids
화학 및 산업
응용 분야
역사DRONEDARONE HYDROCHLORIDE (brand name: Multaq) is an antiarrhythmic drug developed by Sanofi-Aventis. It was approved by the FDA in July 2009 for the treatment of atrial fibrillation and atrial flutter, reducing the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL). The drug was developed to create a treatment that maintains the therapeutic benefits of amiodarone while reducing associated serious side effects such as pulmonary toxicity and thyroid dysfunction. DRONEDARONE HYDROCHLORIDE is usually administered orally in tablet form. The recommended dose is 400 mg twice daily, one tablet in the morning and one in the evening.
용도Dronedarone Hydrochloride can be used for the treatment of atrial fibrillation and atrial flutter in patients who have suffered cardiac arrhythmias.
공급사100 곳
관련 반응
화합물 노트
불러오는 중…